Multiple sclerosis patients face progressive neurodegeneration when their brain's ability to rebuild protective myelin sheaths around nerve fibers fails. This breakdown leaves millions with worsening disabilities as existing treatments cannot restart the stalled repair machinery in chronic lesions.
Researchers have identified neuregulin-1 as a master regulator that can resurrect the brain's natural myelin repair system. In mouse models of chronic demyelination, therapeutic administration of neuregulin-1 successfully restored myelin regeneration by reactivating microglia—the brain's resident immune cells that become dysfunctional in progressive MS. These cells normally clear myelin debris and recycle cholesterol for new myelin synthesis, but in chronic lesions they accumulate lipid droplets and lose their reparative capacity. Neuregulin-1 treatment reversed this "foamy" dysfunctional state, enabling microglia to resume debris clearance and cholesterol processing essential for oligodendrocytes to rebuild myelin.
This discovery addresses a critical gap in MS therapeutics. Current treatments focus on immune suppression to prevent new lesions but cannot reverse existing damage or restart remyelination in chronic plaques. The neuregulin-1 pathway offers a fundamentally different approach—enhancing endogenous repair rather than just blocking inflammation. However, translating these mouse findings to human progressive MS will require careful validation, as microglial behavior and neuregulin-1 signaling may differ between species. The therapeutic window and optimal delivery methods for neuregulin-1 in human brain tissue also remain undefined. Still, targeting this endogenous repair mechanism represents a promising paradigm shift toward regenerative MS therapies.